Drug Profile

Petrelintide/CT 388 - Roche/Zealand Pharma

Alternative Names: CT 388/Petrelintide - Roche/Zealand Pharma

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche; Zealand Pharma
Class Antihyperglycaemics; Hepatoprotectants; Hormones; Obesity therapies; Peptides
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists; Islet amyloid polypeptide replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

12 Mar 2025 Zealand Pharma and Roche enters into a collaboration and license agreement to co-develop and co-commercialise Petrelintide/CT 388
12 Mar 2025 Early research in Obesity in USA, Denmark (unspecified route), prior to March 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com